<?xml version="1.0" encoding="UTF-8"?>
<study api_version="0.6">
  <id>2238</id>
  <name>MDS Whole Genomes</name>
  <active>true</active>
  <user_id>145</user_id>
  <followers>
    <follower>
      <login>som</login>
      <email>som@sanger.ac.uk</email>
      <name>Sarah OMeara</name>
      <id>585</id>
    </follower>
    <follower>
      <login>las</login>
      <email>las@sanger.ac.uk</email>
      <name>Lucy Stebbings</name>
      <id>21</id>
    </follower>
  </followers>
  <managers>
    <manager>
      <login>sm2</login>
      <email>sm2@sanger.ac.uk</email>
      <name>Stuart McLaren</name>
      <id>145</id>
    </manager>
    <manager>
      <login>cdt</login>
      <email>cdt@sanger.ac.uk</email>
      <name>Calli Latimer</name>
      <id>175</id>
    </manager>
    <manager>
      <login>lm5</login>
      <email>lm5@sanger.ac.uk</email>
      <name>Laura Mudie</name>
      <id>587</id>
    </manager>
    <manager>
      <login>cs4</login>
      <email>cs4@sanger.ac.uk</email>
      <name>Claire Hardy</name>
      <id>390</id>
    </manager>
  </managers>
  <owners>
    <owner>
      <login>sm2</login>
      <email>sm2@sanger.ac.uk</email>
      <name>Stuart McLaren</name>
      <id>145</id>
    </owner>
  </owners>
  <!-- Family has been deprecated -->
  <family_id></family_id>
  <created_at>2012-06-08 11:07:20 +0100</created_at>
  <updated_at>2012-11-26 14:20:33 +0000</updated_at>
  <descriptors>
    <descriptor>
      <name>Study description</name>
      <value>Wholegenome libraries will be prepared from at least two serial samples reflecting different stages of disease progression and matched constitutional DNA for 30 Myelodysplastic syndrome patient samples. Five lanes of Illumina HiSeq sequencing will be performed on each of the tumour samples and four lanes for each of the constitutional DNA. Sequencing data will mapped to build 37 of the human reference genome and analysis will be performed to characterize the spectrum of somatic variation present in these samples including single base pair mutations, insertions, deletions as well as larger structural variants and genomic rearrangements. </value>
    </descriptor>
    <descriptor>
      <name>Does this study contain samples that are contaminated with human DNA which must be removed prior to analysis?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Does this study require the removal of X chromosome and autosome sequence?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Does this study require y chromosome data to be separated from x and autosomal data before archival?</name>
      <value>false</value>
    </descriptor>
    <descriptor>
      <name>ENA Project ID</name>
      <value>PRJEB12</value>
    </descriptor>
    <descriptor>
      <name>Abstract</name>
      <value>Cancer is driven by mutation and is typically highly heterogeneous with each tumour represented by multiple subclonal compartments each with its unique spectrum of mutation clusters. Using whole genome library preparation and massively parallel sequencing technology, we aim to the entire genome of 30 paired Myelodysplastic syndrome samples. Bespoke algorithms are being developed to identify the somatically acquired point mutations, insertions and deletions in these samples. This project will give unprecedented insights into mutational processes, cellular repair pathways and gene networks associated with Myelodysplasia development and disease progression. </value>
    </descriptor>
    <descriptor>
      <name>Title</name>
      <value>Myelodysplastic syndrome whole genomes</value>
    </descriptor>
    <descriptor>
      <name>ENA Study Accession Number</name>
      <value>EGAS00001000291</value>
    </descriptor>
    <descriptor>
      <name>Study Visibility</name>
      <value>Hold</value>
    </descriptor>
    <descriptor>
      <name>Do any of the samples in this study contain human DNA?</name>
      <value>Yes</value>
    </descriptor>
    <descriptor>
      <name>Are all the samples to be used in this study commercially available, unlinked anonymised cell-lines?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Study name abbreviation</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>What is the data release strategy for this study?</name>
      <value>managed</value>
    </descriptor>
    <descriptor>
      <name>Will you be using WTSI's standard access agreement?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>How is the data release to be timed?</name>
      <value>standard</value>
    </descriptor>
    <descriptor>
      <name>Reason for delaying release</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Delay for</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Alignments in BAM</name>
      <value>true</value>
    </descriptor>
    <descriptor>
      <name>Please explain the reason for delaying release</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Comment regarding data release timing and approval</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Policy Url</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Policy title</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>EGA DAC Accession Number</name>
      <value>EGAC00001000010</value>
    </descriptor>
    <descriptor>
      <name>EGA Policy Accession Number</name>
      <value>EGAP00001000037</value>
    </descriptor>
    <descriptor>
      <name>ArrayExpress Accession Number</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Has the delay period been approved by the data sharing committee for this project?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>What is the reason for preventing data release?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Has this been approved?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Comment regarding prevention of data release and approval</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>SNP study ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>SNP parent study ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Number of gigabases per sample (minimum 0.15)</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>HMDMC approval number</name>
      <value>10/050</value>
    </descriptor>
    <descriptor>
      <name>Study Type</name>
      <value>Cancer Genomics</value>
    </descriptor>
    <descriptor>
      <name>What sort of study is this?</name>
      <value>genomic sequencing</value>
    </descriptor>
    <descriptor>
      <name>Reference Genome</name>
      <value>Homo_sapiens (CGP_GRCh37.NCBI.allchr_MT)</value>
    </descriptor>
    <descriptor>
      <name>Faculty Sponsor</name>
      <value>Peter Campbell</value>
    </descriptor>
  </descriptors>
</study>
